These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38012900)

  • 1. Corrigendum to "Different roles of bortezomib and ONX 0914 in acute kidney injury" [Int. Immunopharmacol. 82 (2020) 106259].
    Zhang XZ; Han F; Ding CG; Dou M; Wang YX; Xue WJ; Ding XM; Zheng J; Xu CX; Tian PX
    Int Immunopharmacol; 2024 Jan; 126():111189. PubMed ID: 38012900
    [No Abstract]   [Full Text] [Related]  

  • 2. Retraction notice to "Corrigendum to "MLL1 promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by activating the TRIF/NF-κB signaling pathway via H3K4me3 enrichment in the TLR4 promoter region"" [Int. Immunopharmacol. 82 (2020) 106220] [Int. Immunopharmacol. 92 (2021) 107321].
    Zhang Y; Ji T; Ma S; Wu W
    Int Immunopharmacol; 2023 Apr; 117():109865. PubMed ID: 36822094
    [No Abstract]   [Full Text] [Related]  

  • 3. Corrigendum to "MEGF6 prevents sepsis-induced acute lung injury in mice" [Int. Immunopharmacol. 123 (2023) 110727].
    Liang H; Liu G; Zeng W; Fan Q; Nie Z; Hu H; Zhang R; Xie S
    Int Immunopharmacol; 2024 May; 133():111787. PubMed ID: 38641473
    [No Abstract]   [Full Text] [Related]  

  • 4. Corrigendum to "Emodin attenuates acute lung injury in cecal-ligation and puncture rats" [Int. Immunopharmacol. 85 (2020) 106626].
    Guo R; Li Y; Han M; Liu J; Sun Y
    Int Immunopharmacol; 2023 Sep; 122():110700. PubMed ID: 37507324
    [No Abstract]   [Full Text] [Related]  

  • 5. Corrigendum to "Inhibition of MRP4 alleviates sepsis-induced acute lung injury in rats" [Int. Immunopharmacol. 72 (2019) 211-217].
    Xia W; Zhang H; Pan Z; Li G; Zhou Q; Hu D; Liu Y
    Int Immunopharmacol; 2023 Sep; 122():110699. PubMed ID: 37500384
    [No Abstract]   [Full Text] [Related]  

  • 6. Corrigendum to "Paeonol derivative-6 attenuates inflammation by activating ZEB2 in acute liver injury" [Int. Immunopharmacol. 91 (2021) 107235].
    Yang J; Xu L; Wu M; Fang H; Lu Y; Shi C; Wang Y; Li Z; Zhang L; Zhang L
    Int Immunopharmacol; 2021 May; 94():107410. PubMed ID: 33578262
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "Sophoricoside attenuates lipopolysaccharide-induced acute lung injury by activating the AMPK/Nrf2 signaling axis" [Int. Immunopharmacol. 90 (2021) 107187].
    Wu YX; Zeng S; Wan BB; Wang YY; Sun HX; Liu G; Gao ZQ; Chen D; Chen YQ; Lu MD; Pang QF
    Int Immunopharmacol; 2023 Nov; 124(Pt A):111008. PubMed ID: 37806791
    [No Abstract]   [Full Text] [Related]  

  • 8. Corrigendum to "Exosomal miR-127-5p from BMSCs alleviated sepsis-related acute lung injury by inhibiting neutrophil extracellular trap formation" [Int. Immunopharmacol. 123 (2023) 110759].
    Zheng XL; Gu WJ; Zhang F; Zhao FZ; Li LZ; Huang HY; Li LJ; Yi YH; Yin HY; Xu J
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111076. PubMed ID: 37866976
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum to "PAD4 selective inhibitor TDFA protects lipopolysaccharide-induced acute lung injury by modulating nuclear p65 localization in epithelial cells" [Int. Immunopharmacol. 88 (2020) 106923].
    Zhao X; Gu C; Wang Y
    Int Immunopharmacol; 2023 Dec; 125(Pt B):111185. PubMed ID: 37957096
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "GTS-21 attenuates ACE/ACE2 ratio and glycocalyx shedding in lipopolysaccharide-induced acute lung injury by targeting macrophage polarization derived ADAM-17" [Int. Immunopharmacol. 129 (2024) 111603].
    Zhu W; Wang F; Hu C; Zhao Q; Zhang D; Wang X; Hu B; Li J
    Int Immunopharmacol; 2024 May; 132():111914. PubMed ID: 38582738
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "4-Hydroxybenzo[d]oxazol-2(3H)-one ameliorates LPS/D-GalN-induced acute liver injury by inhibiting TLR4/NF-κB and MAPK signaling pathways in mice" [Int. Immunopharmacol. 83 (2020) 106445].
    Wang H; Wei X; Wei X; Sun X; Huang X; Liang Y; Xu W; Zhu X; Lin X; Lin J
    Int Immunopharmacol; 2020 Sep; 86():106722. PubMed ID: 32593975
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "Emerging roles of Sirtuins in alleviating alcoholic liver disease: A comprehensive review" [Int. Immunopharmacol. 108 (2022) 108712].
    Zhao X; Xue X; Wang C; Wang J; Peng C; Li Y
    Int Immunopharmacol; 2023 Jun; 119():110248. PubMed ID: 37160407
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "Thalidomide ameliorate graft chronic rejection in an allogenic kidney transplant model" [Int. Immunopharmacol. 71 (2019) 32-39].
    Zhang Y; Yang Y; Li X; Chen D; Tang G; Men T
    Int Immunopharmacol; 2022 Jun; 107():108584. PubMed ID: 35484056
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "Protective effect of arctiin against Toxoplasma gondii HSP70-induced allergic acute liver injury by disrupting the TLR4-mediated activation of cytosolic phospholipase A2 and platelet-activating factor" [Int. Immunopharmacol. 126 (2023) 111254].
    Lu JM; Xu X; Aosai F; Zhang MY; Zhou LL; Piao LX
    Int Immunopharmacol; 2024 Jan; 127():111422. PubMed ID: 38143162
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "Neutrophil elastase in dexmedetomidine alleviating sepsis-related renal injury in rats" [Int. Immunopharmacol. 122 (2023) 110441].
    Chen L; Li M; Lin Y; Li Y; Liang M; Zeng K
    Int Immunopharmacol; 2024 Feb; 128():111577. PubMed ID: 38281885
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "Laquinimod exerts anti-inflammatory and antiapoptotic effects in retinal ischemia/reperfusion injury" [Int. Immunopharmacol. 88 (2020) 106989].
    Jiang N; Li Z; Li Z; Zhang Y; Yu Z; Wan P; Zhu Y; Li Y; Su W; Zhuo Y
    Int Immunopharmacol; 2022 Jul; 108():108815. PubMed ID: 35534378
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Gypenoside XLIX attenuates sepsis-induced splenic injury through inhibiting inflammation and oxidative stress" [Int. Immunopharmacol. 127 (2024) 111420].
    Xu B; Yang R; Qiang J; Xu X; Zhou M; Ji X; Lu Y; Dong Z
    Int Immunopharmacol; 2024 Apr; 131():111694. PubMed ID: 38368241
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to 'Phaseolin: A 47.5 kDa protein of red kidney bean (Phaseolus vulgaris L.) plays a pivotal role in hypersensitivity induction'. [Int. Immunopharmacol. 19 (2014) 178-190].
    Kumar S; Verma AK; Sharma A; Roy R; Kumar D; Bh G; Tripathi A; Chaudhari BP; Das M; Jain SK; Dwivedi PD
    Int Immunopharmacol; 2020 Jan; 78():105935. PubMed ID: 31645304
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Taxifolin ameliorates Benzo[a]pyrene-induced lung injury possibly via stimulating the Nrf2 signalling pathway" [Int. Immunopharmacol. 96 (2021) 107566].
    Islam J; Shree A; Vafa A; Afzal SM; Sultana S
    Int Immunopharmacol; 2023 Jun; 119():110096. PubMed ID: 37095029
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "Dioscin reduces lipopolysaccharide-induced inflammatory liver injury via regulating TLR4/MyD88 signal pathway" [Int. Immunopharmacol. 36 (2016) 132-141].
    Yao H; Hu C; Yin L; Tao X; Xu L; Qi Y; Han X; Xu Y; Zhao Y; Wang C; Peng J
    Int Immunopharmacol; 2019 Sep; 74():105786. PubMed ID: 31402320
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.